INVO Bioscience Announces One Of The World's Leading Health Sciences Universities, UCSF To Offer The Recently FDA Cleared INVOcell Intravaginal Culture System

MEDFORD, Mass., Sept. 28, 2016 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), a reproductive medical device company who was granted FDA clearance for the first in vivo, vaginal incubation system, the INVOcell, today announced their partnership to offer the INVO Procedure in the state of California with the renowned CA medical teaching institution, UCSF.

"A Simpler Way to Life," the patented INVO Procedure, is a fertility treatment solution that streamlines care, contributing to lower treatment costs compared to traditional IVF. UCSF will be using minimal stimulation that further reduces the risks to the woman, simplifies patient care and lowers costs. Unlike conventional infertility treatments such as in vitro fertilization (IVF), where the eggs and sperm develop into embryos in a laboratory petri dish, the INVOcell utilizes the women's body as a natural incubator making it an in vivo procedure. The INVO fertility treatment procedure may produce live birth rates similar to traditional IVF while adding the benefits of a more natural, simpler and lower cost treatment. 

The UCSF IVF Program, led by Dr. Marcelle Cedars, is not only a full service clinical infertility center but works to push the specialty both to develop new treatment strategies and to increase access to care.

"When we think of family planning, we think of contraception and forget about family building. Our goal is to be able to provide a technique for women of all economic backgrounds to obtain fertility care." says Dr. Marcelle Cedars, Director of the Division of Reproductive Endocrinology at UCSF.  We are hopeful research around this device can help open doors to make fertility care more accessible and more affordable for women in the near future."

"INVO Bioscience is pleased to be partnering with UCSF. It will be the first teaching institution in the state of CA to offer the state of the art INVOcell and INVO procedure. It is a great opportunity to increase access to care and to broaden the experience with this novel in vivo device and simpler treatment procedure" stated Katie Karloff INVO Bioscience's CEO. "By partnering with another CA institution, INVO Bioscience continues its journey to rapidly expand care and access to a more affordable fertility treatment for the 15% of couples that are facing infertility."

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Medford, MA, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

UC Disclaimer

The information stated above was prepared by INVO Biosciences, Inc., and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of INVO, or any of its products, by The Regents of the University of California, its officers, agents and employees.

Contact:

Kathleen Karloff, CEOINVO Bioscience, Inc.978-878-9505 ext. 504

Photo - http://photos.prnewswire.com/prnh/20160927/412663
Logo - http://photos.prnewswire.com/prnh/20160418/356831LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/invo-bioscience-announces-one-of-the-worlds-leading-health-sciences-universities-the-university-of-california-san-francisco-ucsf-to-offer-the-recently-fda-cleared-invocell-intravaginal-culture-system-300335426.html

SOURCE INVO Bioscience, Inc.